博聞科技(600883.SH):提請董事會授權進行轉融通證券出借交易業務
格隆匯 12 月 23日丨博聞科技(600883.SH)公佈,2020年12月23日,公司第十屆董事會第十四次會議、第十屆監事會第十四次會議審議通過了《關於提請董事會授權進行轉融通證券出借交易業務的議案》。
證券出借交易標的證券為公司持有的雲南白藥股票;出借數量不超過48.1萬股(含本數),約佔雲南白藥現總股本的0.038%。
公司為有效盤活存量資產,實現資產在較為安全的保障下增值,提高資產運作效率,增加公司投資收益,給股東帶來一定的回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.